Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Latest on CALR biology and therapeutic targeting in MPNs

Shannon Elf, PhD, University of Utah School of Medicine, Salt Lake City, UT, presents recent advances in the understanding of calreticulin (CALR) biology in myeloproliferative neoplasms (MPNs). Dr Elf highlights the differences between type 1 and type 2 CALR mutations, as well as newly identified pathogenic in-frame mutations. She also discusses the potential of CALR as a therapeutic target, comparing two mutant CALR-targeting monoclonal antibodies, INCA033989 and DMR-001. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.